• Users Online: 103
  • Home
  • Print this page
  • Email this page
Home Current issue Ahead of print Search About us Editorial board Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 12  |  Issue : 1  |  Page : 44-52

Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection

1 Eye Research Center; The Retina and vitreous surgery service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Safety Promotion and Injury Prevention Research Center; Department of Clinical Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Fariba Ghassemi
Eye Research Center, Farabi Eye Hospital, Qazvin Square, Tehran 1336616351
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jovr.jovr_254_15

Rights and Permissions

Purpose: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease. Methods: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist. Results: Patients with a mean age of 30.6 ± 7.4 years received a mean number of 3.3 IVB injections during the 6 months. The mean preinjection vision was 0.6 ± 0.3 and 0.4 ± 0.4 LogMAR in the case and control groups, respectively, with no significant improvement at 6 months. Mean central foveal thickness was 375.3 ± 132.1 and 307.2 ± 84.5 μm in the case and control groups, respectively, and these changed to 401 ± 199.9 (P = 0.65) and 307.7 ± 82.8 μm (P = 0.73) at month 6, respectively. A statistically nonsignificant improvement in ME was observed during the first 3 months in the case group. However, it did not persist up to month 6 on an as-needed basis. IVB injections caused a disproportionate decrease in the thickness of macular subfields. A reduction in disc leakage was observed on FA (P = 0.058). Logistic regression analysis revealed no statistically significant predictive factor for an improvement in visual acuity (VA) and a reduction in foveal thickness. Conclusion: During a 6-month period, IVB injections based on an as-needed protocol provided no statistically significant improvement in VA and ME.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded32    
    Comments [Add]    

Recommend this journal